Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

• the present application relates generally to compositions and methods for treating prostate cancer with a substituted heterocyclic derivative compound, or pharmaceutically acceptable salt thereof, as a bromodomain inhibitor.
• Prostate cancer is the second leading cause of cancer-related death and the most commonly diagnosed cancer in men.
• Prostate cancer tumors are composed primarily of prostate luminal epithelial cells. Differentiation of prostate luminal epithelial cells is controlled in part by Androgen receptor (AR) driven expression of prostate-specific markers. AR are steroid receptors that function as transcription factors and control survival of the cells through mechanisms that remain unclear. Depletion of androgens causes death of normal prostate luminal epithelial cells, which demonstrates the critical role of the AR pathway in their survival. Cancerous prostate cells continue to express AR and their survival also depends on the presence of androgens, which makes androgen deprivation the therapy of choice for patients with advanced prostate cancers.
• AR Androgen receptor
• First-line treatments for prostate cancer aim to reduce circulating androgen levels through the use of androgen deprivation therapies (ADT). While ADT is initially effective at reducing prostate cancer growth, after two to three years of treatment the majority of patients progress to castration-resistant prostate cancer (CRPC) and tumor growth will proceed even in the presence of castration levels of androgen. At this point of disease progression, the number of therapeutic options becomes very limited.
• ADT androgen deprivation therapies
• the present application relates generally to compositions and methods for treating prostate cancer.
• the methods comprise administering a therapeutically effective amount of a bromodomain inhibitor compound (Compound A) having the structure, or a pharmaceutically acceptable salt thereof:
• the aspects and embodiments of the present disclosure provide for methods and pharmaceutical compositions for treating subjects with prostate cancer, such as castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), and anti androgen resistant prostate cancer.
• prostate cancer such as castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), and anti androgen resistant prostate cancer.
• a method of treating prostate cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound A having the structure, or a pharmaceutically acceptable salt thereof; and wherein the prostate cancer is castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), anti- androgen resistant prostate cancer, or any combination thereof.
• the prostate cancer is metastatic.
• the prostate cancer to be treated is in an advanced stage.
• the prostate cancer to be treated has metastasized to regions of the subject’s body other than the prostate gland.
• the prostate cancer to be treated has re occurred in the subject following a significant period of remission.
• the prostate cancer is castration resistant prostate cancer (CPRC).
• CPRC castration resistant prostate cancer
• AR androgen receptor
• the prostate cancer is neuroendocrine prostate cancer (NEPC).
• the method results in substantially inducing cell cycle arrest of the prostate cancer.
• “substantially” is defined as at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% cell cycle arrest of the prostate cancer.
• the method results in completely inducing cell cycle arrest of the prostate cancer.
• the method induces apoptosis of androgen independent cancer cells. In some embodiments, the method results in inducing about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100% apoptosis of the androgen independent cancer cells.
• the method results in at least about 70% reduction of cancer cell proliferation; (b) the method results in from about 70% to about 99% reduction of cancer cell proliferation; (c) the method results in at least about 80% reduction of cancer cell proliferation; (d) the method results in from about 80% to about 99% reduction of cancer cell proliferation; and/or (e) the method results in about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of cancer cell proliferation.
• the method results in at least about 40% reduction of tumor size; (b) the method results in from about 40% to about 99% reduction of tumor size; and/or (c) the method results in about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of tumor size.
• the compound, or a pharmaceutically acceptable salt thereof is adapted for oral administration.
• the compound, or a pharmaceutically acceptable salt thereof is in the form of a tablet, pill, sachet, or capsule of hard of soft gelatin.
• FIG. 1 shows VCaP cells treated with indicated concentrations of Compound A for 3 days. Proliferation was measured both at Day 0 and at Day 3, and percent of growth was determined using Luciferase assay.
• FIG. 2 shows VCaP cells treated with the indicated concentrations of Compound A for 48h.
• KLK3, TMPRSS2, MYC and HEXIM1 genes expression was determined by qPCR.
• FIG. 3 shows LNCaP cells treated with indicated concentrations of Compound A for 3 days. Proliferation was measured both at Day 0 and at Day 3, and percent of growth was determined using Luciferase assay.
• FIG. 4 shows LNCaP cells treated with indicated concentrations of Compound A for 48 hours.
• KLK3, MYC and HEXIM1 genes expression have been determined by qPCR.
• FIG. 5 shows 2-2Rvl cells treated with indicated concentrations of Compound A for 3 days. Proliferation was measured both at Day 0 and at Day 3, and percent of growth was determined using Luciferase assay.
• FIG. 6 shows 22Rvl cells treated with indicated concentrations of Compound A for 48 hours. KLK3, TMPRSS2 , MYC and HEXIM1 genes expression have been determined by qPCR.
• FIG. 7 shows DU145 cells treated with indicated concentrations of Compound A for 3 days. Proliferation was measured both at Day 0 and at Day 3, and percent of growth was determined using Luciferase assay.
• FIG. 8 shows PC3 cells treated with indicated concentrations of Compound A for 3 days. Proliferation was measured both at Day 0 and at Day 3, and percent of growth was determined using Luciferase assay.
• the present invention is directed to methods of treating prostate cancer with a therapeutically effective amount of a bromodomain inhibitor having a structure of Formula (I), or a pharmaceutically acceptable salt thereof.
• the prostate cancer is castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), anti-androgen resistant prostate cancer, or any combination thereof.
• the bromodomain inhibitor is present in an amount to substantially and/or completely induce cell cycle arrest of the prostate cancer cells and induce cell death in prostate carcinoma and neuroendocrine prostate cancer cells.
• the disclosure also encompasses methods whereby metastasis of the prostate cancer is prevented and/or delayed.
• the disclosure encompasses methods whereby prostate cancer cell growth arrest is observed after a short period of administration, e.g., less than about 1 month.
• prostate cancer cell growth arrest is observed in less than about 20, less than about 15, less than about 14, less than about 13, less than about 12, less than about 11, less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, or less than about 3 days.
• the percentage of prostate cancer cell growth arrest observed after any of these time periods can be, for example, about 100%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, or about 20%.
• Example 1 details the ability of Bromo and Extra-Terminal domain inhibitor (BETi) Compound A (is 2-[3-(l,4-dimethyl-lH-l,2,3-triazol-5-yl)-5-[(S)-(oxan- 4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol) to completely arrest cell proliferation and induce cell death in prostate carcinoma and neuroendocrine prostate cancer cells.
• BETi Bromo and Extra-Terminal domain inhibitor
• VCaP cells which exhibit characteristics of clinical prostate carcinoma including expression of Prostate-Specific Antigen (PSA) and androgen receptor (AR);
• LNCaP cells established from a metastatic lesion of human prostatic adenocarcinoma;
• VCaP cells which exhibit characteristics of clinical prostate carcinoma including expression of PSA and AR, are used as a model to study prostate cancer progression and metastasis.
• VCaP cells were treated with BETi Compound A.
• FIG. 1 which graphically shows the percent of VCaP cell growth related to Day 0 and DMSO (Y axis) versus the amount of Compound A (X axis)
• Compound A provided complete (100%) growth arrest for VCaP proliferation at O.luM of Compound A.
• Compound A exhibited cytotoxic effects at the highest concentration (FIG. 1).
• VCaP cells were treated with Compound A and gene expression was measured.
• Two AR target genes Kallikrein Related Peptidase 3 ( KLK3 ) and Transmembrane Serine Protease 2 (TMPRSS2 ) were both downregulated after treatment with Compound A.
• KLK3 Kallikrein Related Peptidase 3
• TMPRSS2 Transmembrane Serine Protease 2
• TMPRSS2 Reduction of expression was also observed for TMPRSS2 with 32.8% and 51.9% of downregulation when 4nM or 40nM of Compound A were respectively administered to cells (FIG. 2 top).
• BET target genes such as MYC and Hexamethylene Bis-Acetamide-Inducible Protein 1 (HEXIM1 ) were also modulated by Compound A.
• HEXIM1 Hexamethylene Bis-Acetamide-Inducible Protein 1
• HEXIM1 was 968.0% and 1257.5% upregulated compared to DMSO when either 4nM or 40nM of Compound A was administered to VCaP cells (FIG. 2 bottom).
• FIG. 3 graphically shows the percent of LNCaP cell growth related to Day 0 and DMSO (Y axis) versus the amount of Compound A (X axis).
• AR signaling was monitored in LNCaP cells after treatment with Compound A and a downregulation of KLK3 was observed with 58.8% and 92.0% of downregulation when 4nM or 40nM were respectively administered to the cells (FIG. 4).
• BETi target genes were also modulated.
• a downregulation of 84.1% ofMYC was observed when 4nM of Compound A was administered to the cells and 93.6% of downregulation was measured when 40nM of Compound A was given to LNCaP cells.
• an upregulation of 446.8% and 533.3% of HEXIM1 was measured when cells were treated with respectively 4nM and 40nM of Compound A (FIG. 4)
• the current standard of care for prostate cancer comprises Androgen Depletion Therapy (ADT) but after a rapid remission, cancer cells eventually acquire resistance and Castration Resistant Prostate Cancer (CRPC) progresses.
• 22Rv.l prostate cancer cells express the AR splice variant AR-V7 which mediates resistance to AR antagonist like Enzalutamide. This cell line was used as a model of CRPC.
• FIG. 5 graphically shows the percent of 22RV.1 cell growth related to Day 0 and DMSO (Y axis) versus the amount of Compound A (X axis).
• 22Rv.l cells were treated with two different concentrations of Compound A (4nM and 40nM).
• AR target genes were both strongly downregulated with 99.9% or 99.8% of downregulation observed for KLK3 when 4nM or 40nM of Compound A was added to the cells.
• a 97.0% or 97.8% of reduction compared to DMSO was measured for TMPRSS2 when cells were treated with 4nM or 40nM of Compound A respectively (FIG. 6 top).
• BET target gene MYC was downregulated with 98.5% downregulation when 4nM of Compound A was added and 99.3% downregulation when cells were treated with 40nM of Compound A.
• cell proliferation of CRPC 22Rv.l is impaired and AR signaling is mis-regulated in cells treated with BETi.
• FIG. 7 visually show a graph of the percent of cell growth of DU145 cells related to Day 0 and DMSO (Y axis) versus the amount of Compound A (X axis).
• PC3 Prostate cancer cells
• PC3 cells were a widely accepted NEPC cell model.
• Fig. 8 visually show a graph of the percent of cell growth of PC3 cells related to Day 0 and DMSO (Y axis) versus the amount of Compound A (X axis).
• the data show the ability of BETi Compound A to substantially and/or completely arrest cell proliferation and induce cell death in Prostate Carcinoma cells, and support the use of Compound A and structurally related compounds as a new and targeted therapy for solid tumors.
• Tricyclic compounds useful as bromodomain inhibitors are disclosed in U.S. Patent Application Ser. No. 14/580,355 (U.S. Patent No. 9,458,155).
• Compound A is 2-[3-(l,4-dimethyl- lH-l,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7- yl]propan-2-ol, which has the following structure: or the pharmaceutically acceptable salt thereof.
• the above compound has the chemical formula of C30H33N5O2 and a molecular weight of 495.62. The synthesis of this compound is disclosed in in U.S. Patent Application Ser. No. 14/580,355 (U.S. Patent No. 9,458,155).
• Pharmaceutically acceptable salts of include, but are not limited to, acid addition salts, formed by reacting the compound with a pharmaceutically acceptable inorganic acid, such as, for example acid addition salts, formed by reacting the compound with a pharmaceutically acceptable inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxy ethanesulfonic acid,
• compositions are formulated into pharmaceutical compositions.
• Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that are used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
• a pharmaceutical composition disclosed herein comprises one or more pharmaceutically acceptable carriers, such as an aqueous carrier, buffer, and/or diluent. Administration of the compounds and compositions described herein can be effected by any method that enables delivery of the compounds to the site of action.
• enteral routes including oral, gastric or duodenal feeding tube, rectal suppository and rectal enema
• parenteral routes injection or infusion, including intraarterial, intracardiac, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, intrathecal, intravascular, intravenous, intravitreal, epidural and subcutaneous), inhalational, transdermal, transmucosal, sublingual, buccal and topical (including epicutaneous, dermal, enema, eye drops, ear drops, intranasal) administration, although the most suitable route may depend upon for example the condition and disorder of the recipient.
• compositions suitable for oral administration are presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion.
• the active ingredient is presented as a bolus, electuary or paste.
• Pharmaceutical compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents.
• Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
• the tablets are coated or scored and are formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
• the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
• the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
• Suitable nontoxic solid carriers also include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
• the compounds described herein may be combined or coordinately administered with a suitable carrier or vehicle depending on the route of administration.
• carrier means a pharmaceutically acceptable solid or liquid filler, diluent or encapsulating material.
• a water-containing liquid carrier can comprise pharmaceutically acceptable additives such as acidifying agents, alkalizing agents, antimicrobial preservatives, antioxidants, buffering agents, chelating agents, complexing agents, solubilizing agents, humectants, solvents, suspending and/or viscosity-increasing agents, tonicity agents, wetting agents or other biocompatible materials.
• pharmaceutically acceptable additives such as acidifying agents, alkalizing agents, antimicrobial preservatives, antioxidants, buffering agents, chelating agents, complexing agents, solubilizing agents, humectants, solvents, suspending and/or viscosity-increasing agents, tonicity agents, wetting agents or other biocompatible materials.
• Some examples of the materials which can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen free water; isotonic saline; Ringer's solution, ethyl
• wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions, according to the desires of the formulator.
• antioxidants examples include water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabi sulfite, sodium sulfite and the like; oil- soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and metal-chelating agents such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
• water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabi sulfite, sodium sulfite and the like
• oil- soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin
• compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.
• excipients are known in the art.
• filling agents include lactose monohydrate, lactose anhydrous, and various starches
• binding agents include various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, such as Avicel ® PHI 01 and Avicel ® PHI 02, microcrystalline cellulose, and silicified microcrystalline cellulose (ProSolv SMCCTM).
• Suitable lubricants may include colloidal silicon dioxide, such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
• colloidal silicon dioxide such as Aerosil ® 200, talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
• sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame.
• sweeteners may include any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame.
• flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
• preservatives examples include potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride.
• Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by for example filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Any pharmaceutically acceptable sterility method can be used in the compositions of the invention.
• composition comprising the compounds described herein, or the salts thereof, will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the method of administration, the scheduling of administration, and other factors known to practitioners.
• the present application provides methods of treating prostate cancer using any one of the bromodomain inhibitors described herein, or pharmaceutically acceptable salts thereof.
• a therapeutically effective amount of the bromodomain inhibitor can be used.
• the therapeutically effective amount of the bromodomain inhibitor, or a pharmaceutically acceptable salt thereof is in an amount to substantially induce cell cycle arrest of the prostate cancer cell.
• the therapeutically effective amount of the bromodomain 1 inhibitor, or a pharmaceutically acceptable salt thereof is in an amount to completely induce cell cycle arrest of prostate cancer cell.
• the therapeutically effective amount of the bromodomain inhibitor, or a pharmaceutically acceptable salt thereof is in an amount to induce apoptosis of androgen independent cancer cells.
• the methods result in substantially inducing cell cycle arrest of prostate cancer cell, wherein “substantially” is defined as at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% cell cycle arrest of the prostate cancer cell.
• the percent cell cycle arrest of the prostate cancer cells can be measured using any clinically acceptable technique.
• the methods result in completely inducing cell cycle arrest of the prostate cancer cells.
• the cell cycle arrest of the prostate cancer cells can be measured using any clinically acceptable technique.
• the methods result in inducing apoptosis of androgen independent cancer cells.
• the methods can result in inducing about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100% apoptosis of androgen independent cancer cells.
• Apopotosis of the androgen independent cancer cells can be measured using any clinically acceptable technique.
• a method of treating prostate cancer in a subject in need thereof comprising administering to the subject a composition comprising bromodomain inhibitor, or a pharmaceutically acceptable salt thereof.
• the prostate cancer can be castration resistant prostate cancer (CPRC), neuroendocrine prostate cancer (NEPC), anti-androgen resistant prostate cancer, or any combination thereof.
• the prostate cancer is castration resistant prostate cancer (CPRC).
• the prostate cancer is neuroendocrine prostate cancer (NEPC).
• the prostate cancer is anti-androgen resistant prostate cancer.
• the prostate cancer to be treated can be in an advanced stage. In any of the embodiments described herein, the prostate cancer can be metastatic. In any of the embodiments described herein, the prostate cancer to be treated can have metastasized to regions of the patient's body other than the prostate gland. In any of the embodiments described herein, the prostate cancer to be treated can have re-occurred in the patient following a significant period of remission.
• the method can result in (a) at least about 40% reduction of cancer cell proliferation; (b) from about 40% to about 99% reduction of cancer cell proliferation; and/or (c) in about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of cancer cell proliferation.
• the method results in at least about 40% reduction of cancer cell proliferation.
• the method results in from about 40% to about 99% reduction of cancer cell proliferation.
• the method results in about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of cancer cell proliferation.
• the method results in (a) at least about 40% reduction of tumor size; (b) from about 40% to about 99% reduction of tumor size; and/or (c) about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of tumor size.
• the method results in at least about 40% reduction of tumor size.
• the method results in from about 40% to about 99% reduction of tumor size.
• the method results in about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99% reduction of tumor size.
• Administration may be via any route of administration.
• Non-limiting examples include nasal, sublingual, buccal, rectal, intravenous, intra-arterial, intradermal, intraperitoneal, intrathecal, intramuscular, epidural, intracerebral, intracerebroventricular, transdermal, or any combination thereof.
• an appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
• an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
• Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
• the bromodomain inhibitor is adapted for oral administration.
• Suitable forms for oral administration include, but are not limited to, a tablet, pill, sachet, or capsule of hard of soft gelatin.
• the compounds or compositions described herein of the invention may be packaged together with, or included in a kit along with instructions or a package insert.
• Such instructions or package inserts may address recommended storage conditions, such as time, temperature and light, taking into account the shelf-life of the bromodomain inhibitor or the salts thereof.
• Such instructions or package inserts may also address the particular advantages of the compounds described herein or derivatives or salts thereof, such as the ease of storage for formulations that may require use in the field, outside of controlled hospital, clinic or office conditions.
• kits comprising one or more containers filled with one or more pharmaceutical compositions disclosed herein.
• kits may include, for instance, containers filled with an appropriate amount of a pharmaceutical composition, either as a powder, a tablet, to be dissolved, or as a sterile solution.
• a pharmaceutical composition either as a powder, a tablet, to be dissolved, or as a sterile solution.
• Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
• the bromodomain inhibitor or the salts thereof may be employed in conjunction with other therapeutic compounds.
• the kit may comprise one or more devices, wherein the device may be sealed within a first protective packaging, or a second protective packaging, or a third protective packaging, that protects the physical integrity of the product.
• One or more of the first, second, or third protective packaging may comprise a foil pouch.
• the kit may further comprise instructions for use of the device.
• the kit contains two or more devices.
• the kit may comprise a device, and may further comprise instructions for use.
• the instructions may comprise visual aid/pictorial and/or written directions to an administrator of the device.
• administering includes prescribing for administration as well as actually administering, and includes physically administering by the subject being treated or by another.
• subject refers to any subject, patient, or individual, and the terms are used interchangeably herein.
• the terms “subject,” “patient,” and “individual” includes mammals, and, in particular humans.
• the term “subject,” “patient,” or “individual” intends any subject, patient, or individual having or at risk for a specified symptom or disorder.
• the phrase “therapeutically effective” or “effective” in context of a “dose” or “amount” means a dose or amount that provides the specific pharmacological effect for which the compound or compounds are being administered. It is emphasized that a therapeutically effective amount will not always be effective in achieving the intended effect in a given subject, even though such dose is deemed to be a therapeutically effective amount by those of skill in the art. For convenience only, exemplary dosages are provided herein. Those skilled in the art can adjust such amounts in accordance with the methods disclosed herein to treat a specific subject suffering from a specified symptom or disorder. The therapeutically effective amount may vary based on the route of administration and dosage form.
• treatment includes reducing, ameliorating, or eliminating (i) one or more specified symptoms and/or (ii) one or more symptoms or effects of a specified disorder.
• prevention includes reducing, ameliorating, or eliminating the risk of developing (i) one or more specified symptoms and/or (ii) one or more symptoms or effects of a specified disorder.
• “Pharmaceutically acceptable salt” includes both acid and base addition salts.
• a pharmaceutically acceptable salt of any one of the substituted heterocyclic derivative compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
• Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
• “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
• acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
• Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitro-benzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
• Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
• “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid.
• Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
• Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
• Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N- methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
• Compound A refers to is 2-[3-(l,4-dimethyl- lH-l,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7- yl]propan-2-ol.
• the following example evaluates the ability of BETi Compound A to completely arrest cell proliferation and induce cell death in prostate carcinoma and neuroendocrine prostate cancer cells.
• VCaP, LNCaP, 22Rv.l, DU145 and PC3 cancer cell lines were obtained from ATCC.
• VCaP were cultured in DMEM media supplemented with 8% FBS
• LNCaP, 22Rv.1 and DU145 were cultured in RPMI1640 media supplemented with 10% FBS
• PC3 were cultured in F12K media supplemented with 10% FBS.
• Cells were plated in a 96-well format and were allowed to adhere 24h before treatment. Drugs were titrated 1:3 from 1 ⁇ M to O.lnM with 9 doses in triplicate. Cell proliferation was measured on the day of treatment (Day 0) and on Day 3 using Cell Titer- Glo reagent (Promega) according to the manufacturer’s instructions. Cell growth normalized to the DMSO vehicle control and to Day 0 was fitted by nonlinear regression using GraphPad Prism 7.03 (GraphPad Software, Inc.).
• Compound A causes a complete growth arrest and induces cell death of Prostate Carcinoma cells.
• VCaP cells exhibit characteristics of clinical prostate carcinoma including expression of Prostate-Specific Antigen (PSA) and androgen receptor (AR), and are used as a model to study prostate cancer progression and metastasis.
• PSA Prostate-Specific Antigen
• AR androgen receptor
• BETi BET inhibitor
• Compound A affects VCaP proliferation causing a complete (100%) growth arrest at O.luM.
• Compound A exhibits cytotoxic effect (FIG. 1).
• VCaP cells have been treated with Compound A and gene expression was measured.
• Two AR target genes Kallikrein Related Peptidase 3 ( KLK3 ) and Transmembrane Serine Protease 2 (TMPRSS2 ) are both downregulated after treatment with Compound A.
• KLK3 Kallikrein Related Peptidase 3
• TMPRSS2 Transmembrane Serine Protease 2
• TMPRSS2 A downregulation was also observed for TMPRSS2 with 32.8% and 51.9% of downregulation when 4nM or 40nM of Compound A were respectively administered to cells (FIG. 2 top).
• BET target genes such as MYC and Hexamethylene Bis- Acetamide-Inducible Protein 1 (HEXIM1 ) were also modulated by Compound A.
• HEXIM1 Hexamethylene Bis- Acetamide-Inducible Protein 1
• HEXIM1 was 968.0% and 1257.5% upregulated compared to DMSO when either 4nM or 40nM of Compound A was administered to VCaP cells (FIG. 2 bottom).
• AR signaling was monitored in LNCaP cells after treatment with Compound A and downregulation of KLK3 was observed with 58.8% and 92.0% of downregulation when 4nM or 40nM were respectively administered to the cells (FIG.4).
• BETi target genes were also modulated.
• a downregulation of 84.1% of MYC was observed when 4nM of Compound A was administered to the cells and 93.6% of downregulation was measured when 40nM of Compound A was given to LNCaP cells.
• an upregulation of 446.8% and 533.3% of HEXIM1 was measured when cells were treated with respectively 4nM and 40nM of Compound A (FIG. 4)
• Compound A impairs proliferation of Castration Resistant Prostate Cancer cells.
• ADT Androgen Depletion Therapy
• CRPC Castration Resistant Prostate Cancer
• AR target genes were both strongly downregulated with 99.9% or 99.8% of downregulation observed for KLK3 when 4nM or 40nM of Compound A was added to the cells.
• a 97.0% or 97.8% of reduction compared to DMSO was measured for TMPRSS2 when cells weretreated with 4nM or 40nM of Compound A respectively (FIG. 6 top).
• BET target gene MFC was downregulated with 98.5% downregulation when 4nM of Compound A was added and 99.3% downregulation when cell were treated with 40nM of Compound A.
• HEXIM1 was upregulated and 31% of induction was observed when cells were treated with 4nM of Compound A, while a 91.5% of upregulation was measured when cells were treated with 40nM of Compound A (FIG. 6 bottom).
• Compound A strongly reduces proliferation of Neuroendocrine prostate cancer cells.
• a subset of CRPC patients develops an AR-independent disease characterized by a Neuroendocrine (NE) phenotype with low or absent AR expression.
• NE Neuroendocrine
• Prostate cancer cells DU145 are AR negative cell lines which do not respond to androgens. To test the effect of BETi in AR negative cells, DU145 were treated with Compound A and a 61.9% reduction of DU145 proliferation was observed (FIG. 7).
• PC3 are another AR negative cell line widely accepted as NEPC cell model.
• PC3 cells were treated with Compound A.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=80952117

Family Applications (1)

Country Status (6)

Cited By (2)

Citations (4)

Family Cites Families (11)

• 2022
  • 2022-03-07 US US17/653,717 patent/US12016847B2/en active Active
  • 2022-03-10 WO PCT/US2022/019662 patent/WO2022192481A1/en not_active Ceased
  • 2022-03-10 KR KR1020237034510A patent/KR20230156107A/ko active Pending
  • 2022-03-10 JP JP2023555527A patent/JP2024510975A/ja active Pending
  • 2022-03-10 CN CN202280032513.3A patent/CN117241797A/zh active Pending
  • 2022-03-10 EP EP22713194.3A patent/EP4304589A1/en active Pending

Patent Citations (4)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events